http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#Head
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#assertion
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#provenance
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#pubinfo
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#assertion
http://purl.obolibrary.org/obo/DOID_1040
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1040
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01073
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association
http://www.w3.org/2000/01/rdf-schema#label
fludarabine phosphate injection is a nucleotide metabolic inhibitor indicated for the treatment of adult patients with b cell chronic lymphocytic leukemia cll who have not responded to or whose disease has progressed during treatment with at least one standard alkylating agent containing regimen benefit in treatment naive or non refractory cll patients is not established 1 1 important limitations fludarabine phosphate should not be used in patients with severe renal impairment creatinine clearance less than 3 ml min 1 73 m 2 5 7 fludarabine phosphate injection is indicated for the treatment of adult patients with b cell chronic lymphocytic leukemia cll who have not responded to or whose disease has progressed during treatment with at least one standard alkylating agent containing regimen the safety and effectiveness of fludarabine phosphate injection in previously untreated or non refractory patients with cll have not been established fludarabine phosphate injection should not be used in patients with severe renal impairment creatinine clearance less than 3 ml min 1 73 m 2 see warnings and precautions 5 7
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01073
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#provenance
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#pubinfo
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#sig
http://purl.org/nanopub/x/hasSignature
YeU/DW6PY+UXoYcegbmX8nhXb4s9oeKYCNLRVlk+sQgQHEJocWTwODcOxEDbjjfYRlfKfxBrBcI9z/YiylcS96HD1spRUxAYx5MaqJgiQ0atdwkFPw/nqbYs+BFezqfjhHXrc98YW8ttngnzmwsVGzszblcJKP7zUUR/e3MLOWY=
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8
http://purl.org/dc/terms/created
2021-06-13T14:13:05.574+02:00
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs